What is Kinnate Biopharma Inc. (KNTE)?

Kinnate Biopharma Inc. (KNTE) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of KNTE?

The current price of KNTE is $2.65. Prices are updated in real time on Stocks360.

What is KNTE's price-to-earnings (PE) ratio?

KNTE's trailing twelve-month PE ratio is -1.10, based on current price and earnings per share data available on Stocks360.

What is KNTE's market capitalization?

KNTE's market capitalization is $124,990,960.00, placing it in the small-cap tier.

Kinnate Biopharma Inc. (KNTE)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$2.65

Market Cap

$124.99M

PE (TTM)

-1.10

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.34

Day Range

$2.64 – $2.68

52-wk Range

$1.04 – $7.19

Avg Volume

N/A

Volume

2.12M

Kinnate Biopharma Inc. (KNTE) is a publicly traded company in the Healthcare sector. Latest price: $2.65. Market cap $124.99M. Trailing PE -1.10. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

May 9, 2024

EPS $-0.73 vs est. $-0.34

Missed by $0.39

Proprietary Signals

Signal snapshot temporarily unavailable.

About Kinnate Biopharma Inc.

Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-1.10×
P/S (TTM)	0.00×
P/B	0.77×
P/FCF (TTM)	-1.25×
EV / EBITDA	-0.60×
EV / Sales	0.00×
Earnings Yield	-91.27%
Free Cash Flow Yield	-80.04%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$71.17M
Net Income (TTM)	-$114.08M
Free Cash Flow (TTM)	-$100.04M
Net Debt	-$53.82M
Working Capital	$146.18M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-58.86%
Return on Invested Capital	-73.23%